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Background: Tick-borne encephalitis (TBE) is an infectious disease endemic to large parts of Europe and Asia.
Diagnosing TBE often relies on the detection of TBEV-specific antibodies in serum and cerebrospinal fluid (CSF)
as viral genome is mostly not detectable once neurological symptoms occur.
Objectives: We evaluated the performance of TBEV IgM and IgG ELISAs in both serum and CSF of confirmed
TBEV patients and discuss the role of (CSF) serology in TBEV diagnostics.
Study design: For the assay evaluation we collected specimen from confirmed TBEV patients. Assay specificity
was assessed using sera from patients with a related flavivirus infection or other acute infection. A selected ELISA
assay was used to analyze TBEV-specific antibodies in CSF and to evaluate the use in confirming TBE diagnosis.
Results: In this study the overall sensitivity of the IgM TBEV ELISAs was acceptable (94 -100 %). Four out of five
IgM ELISA’s demonstrated an excellent overall specificity from 94 -100% whereas a low overall specificity was
observed for the IgG TBEV ELISAs (30-71%). Intrathecal antibody production against TBEV was demonstrated in
a subset of TBE patients.
Conclusions: In four out of five ELISAs, IgM testing in serum and CSF of TBE patients is specific and confirmative.
The lack of IgG specificity in all ELISAs emphasizes the need of confirmatory testing by virus neutralisation,
depending on the patient’s background and the geographic location of exposure to TBEV. A CSF-serum IgG
antibody index can support the diagnosis specifically in chronic disease or once IgM has disappeared.
1. Background
Tick-borne encephalitis (TBE) is a zoonotic, infectious disease en-
demic to large parts of Europe and Asia [1,2]. It is caused by the tick-
borne encephalitis virus (TBEV, family flaviviridae, genus flavivirus).
Three subtypes can be distinguished, namely the European (TBEV-Eur),
Siberian (TBEV-Sib) and Far Eastern (TBEV-FE) subtypes with a close
antigenic relationship and inducing cross-protection. [3,4] TBEV is
transmitted to humans through tick bites from Ixodes spp, but sporadic
transmission by consumption of unpasteurised dairy products from in-
fected livestock has also been reported. [5] In Europe, the prevalence of
TBEV is increasing [2,6] and recently the first autochthonous cases
were reported in the Netherlands [7,8].
The majority (75%) of TBEV infections are subclinical or asympto-
matic. [9] Symptoms caused by TBEV vary from mild to severe, de-
pending on a person’s age and subtype, with severity increasing with
age [10,11]. Typically, an infection with TBEV-Eur results in a biphasic
course of illness, starting with a viraemic phase with non-specific, in-
fluenza-like symptoms, including fever, followed by an asymptomatic
interval lasting several days [9–11]. In the second phase, which occurs
in 72–87% of the symptomatic cases [9], patients may develop neuro-
logical symptoms, ranging from mild meningitis to severe encephalitis,
with or without nerve paralysis and myelitis [10–12]. Neurological
symptoms usually clear up completely, although headaches and
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cognitive impairment can last up to 6–12 months [9]. Exact data on
case fatality rates of the eastern subtypes are lacking, but case fatality is
thought to be much higher in TBEV-FE infections (20–40% [1,13]) than
in TBEV-Sib (2–3% [1]) and TBEV-Eur (0.8–1.4% [10,11]). Infections
of all subtypes can be prevented by vaccination, but vaccination
breakthrough has been described [14–16].
Upon infection with TBEV, viral RNA is usually detected in blood or
serum only during the first phase of infection, in which the patient is
asymptomatic or symptoms are non-specific. Once neurological symp-
toms are manifest, TBEV RNA is rarely detected in blood and cere-
brospinal fluid (CSF) [17], although persistent viraemia in an im-
munocompromised patient has been reported [18]. Usually, diagnosing
TBEV infection relies on the detection of TBEV-specific antibodies in
serum and CSF. TBEV-specific IgM antibodies are typically detected in
serum when neurological symptoms are present. In CSF, the IgM re-
sponse peaks later than in serum after the onset of neurological
symptoms; usually it is detectable from the second week [19]. Speci-
fically in TBEV-Sib infections, the neurological symptoms may develop
more rapidly and be present before IgM seroconversion occurs [20].
The current laboratory-case definitions state that brain-derived IgM
detection in CSF confirms the diagnosis of TBEV encephalitis. [21,22] A
CSF-serum antibody index can be used to differentiate between blood-
derived and brain-derived specific antibody fraction [23]. After TBEV
infection, specific, neutralising IgG have lifelong persistence in pro-
tecting against reinfection, whereas IgM is typically detected up to 3
months, with persistence occasionally lasting up to 9 months [24,25].
Unfortunately, the interpretation of TBEV serology is severely ham-
pered by extensive cross-reactivity among flaviviruses and the phe-
nomenon of original antigenic sin, where an acute flavivirus infection
might boost cross-reactive antibodies due to previous infection with, or
vaccination against, another flavivirus [26,27]. Therefore, the choice of
serological test in a diagnostic setting needs careful consideration and
an evaluation of the available tests using sample cohorts relevant for
the local setting.
2. Objectives
We have evaluated the analytical and diagnostic performance of five
commercially available TBEV IgM and IgG ELISAs, using a panel of
virus-neutralisation and/or RT-PCR-confirmed TBEV patients. TBEV-
specific antibodies in CSF were determined by an ELISA with a specific
CSF protocol, applicable within routine diagnostics. The results were
evaluated and the use of CSF serology in confirming TBE diagnosis is
discussed.
3. Study design
3.1. Evaluation cohorts
For the assay evaluation we collected 18 serum and plasma samples
from TBEV-infected patients. TBEV infection was confirmed by the
presence of TBEV neutralising antibodies, and in three patients TBEV
genomic RNA was detected by a TBEV-specific RT-PCR (Table 1). Be-
tween 2010 and 2017 material was collected from three reference la-
boratories: 1) Erasmus MC Rotterdam, the Netherlands; 2) the Faculty
of Medicine in Ljubljana, Slovenia; and 3) the Helsinki University
Hospital, Helsinki, Finland. Ethical approval to anonymously analyse
the used samples of all patients was obtained from the Erasmus MC
Medical Ethical Committee (MEC-2015-306).
Assay specificity was assessed using a total of 42 sera from 42 pa-
tients with a related flavivirus infection, i.e. dengue virus (DENV),
Japanese encephalitis virus (JEV) and zika virus (ZIKV), or vaccinated
against a related flavivirus, i.e. JEV and yellow fever virus (YFV). In
addition, assay specificity was assessed using 17 sera or plasma samples
from patients with an acute human cytomegalovirus infection or
Epstein-Barr virus infection and 10 sera from patients with a confirmed
chikungunya virus infection. Given the lack of detailed clinical in-
formation on the control groups, e.g. flavivirus vaccination history and
previous flavivirus exposure, all control-group samples were tested in
the TBEV VNT so that the presence of antibodies reactive against TBEV
could be ruled out. To evaluate the role of CSF serology, we collected
eight paired/serum CSF samples from clinical TBE patients, which were
laboratory confirmed by the TBEV virus neutralisation test (VNT).
3.2. Immunoassays for TBEV antibody detection
Based on the presence of European Union CE certification marking,
TBEV ELISAs of five different manufacturers were selected. These were:
1. Serion ELISA TBE Virus (Virion\Serion, Würzburg, Germany; TBEV
strain Moscow B-4); 2. Immunozym FSME (Progen, Heidelberg,
Germany; TBEV strain Neudörfl); 3. Reagena TBE (Reagena, Toivala,
Finland; TBEV-Eu strain Kumlinge A52); 4. Euroimmun Anti-TBE Virus
ELISA (Euroimmun, Lübeck, Germany; TBEV strain K23); and 5.
Enzygnost Anti-TBE (Siemens, Marburg, Germany; strain K23). All
ELISAs indirectly detect TBEV-directed antibodies using inactivated
TBEV virus antigen coated wells, except for Reagena IgM and IgG,
which are capture ELISAs that use recombinant TBEV antigen. The
ELISAs were carried out and the results were interpreted according to
the manufacturers’ instructions.
3.3. Virus neutralisation test
Virus neutralisation is the gold standard in discriminating flavivirus
serology. The presence of TBEV-specific neutralising antibodies was
determined using an in-house micro-neutralisation assay. Twofold
serum dilution series were incubated with 100 TCID50 of TBEV strain
(Neudörfl H2J (Isolate Arb 131)) at 36.5 °C, and transferred to Vero
Table 1
Evaluation cohorts.
Sensitivity panel
TBEV confirmed samples Confirmation level
VNT positive 15
VNT and PCR positive 3
Total 18
Background information Gendera #patients(%)
Male 8(73%)
Female 3(27%)
Reported symptoms #patients(%)
Fever 6(33%)
Headache 9(50%)
Meningitis and/or encephalitis 7(39%)
Reported tick bite 6(33%)
Specificity panel
Flavivirus Confirmation level # VNT
TBEV
DENV patients DENV IgM+ IgG+ 8 neg
DENV NS1+IgM+ 9 neg
JEV patients JEV IgG+ JEV VNT+ 2 neg
ZIKV patients ZIKV IgM+ IgG+ZIKVVNT + 9 neg
ZIKV IgM+ IgG- ZIKV VNT + 1 neg
YFV post vaccination YFV IgG+ 10 neg
JEV post vaccination JEV IgG+ JEV VNT+ 2 neg
Acute infection with non-flavivirus
CMV CMV IgM+ IgG+CMV avidity low 8 neg
EBV EBV NA IgG- EBV VCA IgM+PCR EBV
+
9 neg
CHIKV CHIKV IgM+ IgG+, CHIKV VNT + 10 neg
CMV: cytomegalovirus, CHIKV: Chikungunya virus, DENV: dengue virus, EBV:
Epstein Barr virus, JEV: Japanese encephalitis virus, TBEV: tick-borne en-
cephalitis virus, VNT: virus neutralisation test, YFV: yellow fever virus, ZIKV:
Zika virus, neg: negative, #:number
a All other patients unknown.
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cells (Vero ATCC CCL-81) for 1 h. Then the Vero cells were refreshed
with Dulbecco MEM Eagle Medium (DMEM) supplemented with 1%
Penicillin/streptomycin (LO DE17-602E), 1% L-Glutamine (LO BE17-
605E), 1M HEPES (BE17-737E), 7,5% NaHCO3 (BE17-613E), 3%
Foetal Bovine Serum (FBS, F7524) and incubated at 36.5 °C and 5%
CO2. TBEV infection was determined by cytopathic effect at 7 days post
infection. A VNT TBEV reciprocal titre of ≥1/32 was considered as
positive.
3.4. Analysis
Sensitivity values for IgM and IgG were calculated for each of the
five test systems by using the TBEV VNT as a gold standard for IgG,
while an alternative strategy was used for IgM. In the absence of a gold
standard, an IgM result (positive, negative or equivocal) obtained
by≥ three of the five test systems was interpreted as the correct result.
Equivocal results were consistently interpreted as a positive result in all
calculations for IgM and IgG sensitivity and specificity.
Specificity values were calculated by analysing the amount of re-
activity in the TBEV ELISAs, of sera from patients with confirmed other
viral infections, not responsive in TBEV VNT.
3.5. TBEV RNA detection
TBEV RNA detection in CSF was performed using an in-house real-
time reverse transcription-polymerase chain reaction. [28]
3.6. Analysis of CSF
The first step when calculating a CSF-serum Antibody Index (AI) is
the quantification of the blood-brain barrier (BBB) functioning, which is
done by calculating the age-dependent albumin CSF-serum quotient.
Next, a CSF-serum immunoglobulin quotient has to be calculated to
correct for high levels of intrathecal IgG. The AI is the ratio between the
CSF-serum quotient of the specific TBEV IgG antibodies and the total
IgG antibodies, following Reiber. [23,29] Theoretically, the normal AI
value must be AI= 1.0, whereas clinically relevant, pathological AI
values are> 1.5. [23].
Albumin and total IgG in both serum and CSF were measured by
nephelometry at the laboratory of clinical chemistry at Erasmus MC.
Quantitative detection, of both anti-TBEV IgM and IgG in paired serum
and CSF, was carried out with the Euroimmun TBEV ELISA (Lübeck,
Germany), which is the testing benchmark in our laboratory, using the
included CSF protocol. Measured immunoglobulin titres were quanti-
fied by transforming the optical density (at 450 nm) into mg/L, using
four different CSF calibrators, in accordance with the manufacturer’s
instructions.
4. Results
4.1. Sensitivity comparison
The sensitivity of the five commercial ELISAs was assessed using 18
serum samples of confirmed European TBEV patients (Table 1, Fig. 1,
Suppl. Table 1). Serion, Progen and Siemens ELISAs had a sensitivity of
94% for IgG, while Reagena and Euroimmun ELISAs had a sensitivity of
83%. For IgM detection, the ELISAs demonstrated a comparable sensi-
tivity (94–100%).
4.2. Specificity comparison
To address the amount of cross-reactivity, we assessed the specifi-
city of the five commercial assays by using a panel of 42 sera from
patients infected or vaccinated with related flaviviruses and a panel of
27 sera from patients with non-related viral infections (Tables 1 and
Suppl. Table 1). All commercial TBEV IgG tests scored low on specificity
when tested with a related flavivirus panel, with specificities ranging
from 12 to 67%. Of the TBEV IgM assays, only the Reagena ELISA de-
monstrated 100% specificity in the flavivirus panel. For the panel of
sera from non-flavivirus infections, all ELISAs demonstrated 100%
specificity for IgM, while the specificity for IgG ranged between 59 and
89%.
4.3. Serum-CSF serology
To assess the added value of comparative serum-CSF serology in
confirming the diagnosis of TBE in clinically suspect patients, we ret-
rospectively analysed eight serum-CSF pairs obtained from patients
infected in different areas in Europe and presenting with neurological
signs of TBE. All patients had an intact BBB and no evidence of poly-
clonal intrathecal antibody production. The serological diagnosis was
confirmed by performing a TBEV VNT in all patients (Table 2). Paired
serum-CSF samples were tested by using the CSF protocol of the
Euroimmun assay, which is routinely performed in our laboratory and
had acceptable performance characteristics. All patients had detectable
levels of IgM in both serum and CSF, which is considered to be con-
firmative for the diagnosis of TBE. [21,22] IgG levels were detected in
both serum and CSF in seven of the eight patients. The IgG TBEV AI was
calculated in these seven patients and in five of them it was found to be
above the manufacturer’s cut-off of 1.5, which is indicative of the
presence of intrathecal IgG immunoglobulins directed against TBEV. In
two patients the index was<1, which is interpreted as non-patholo-
gical.
5. Discussion
TBE has been a serious and notifiable disease in the EU since 2012.
Between 2012 and 2016 some 12,500 TBE cases were reported to the
ECDC, by 23 EU countries. While the overall TBE notification rate has
remained stable, increased geographic prevalence has been observed.
[30] Accurate diagnostics are the cornerstone of an adequate clinical
and public-health response, including the implementation of surveil-
lance programmes [31]. The routine detection of TBEV-specific anti-
bodies in serum and CSF is a key tool for diagnosing TBEV infection
[22]. However, flavivirus serology is known to be complex and the
market supply of commercial tests is rather diverse. A serological assay
that can thoroughly analyse both clinical sample types is thus a key
requirement for obtaining reliable test results.
Although a few studies have evaluated commercially available
TBEV ELISAs [32–35], the putative cross-reactive panels in these stu-
dies were limited. This is an important study limitation because TBEV
testing in diagnostic laboratories is often part of a much broader dif-
ferential diagnostic panel of viruses, while (previous) exposure to re-
lated flaviviruses might interfere with test interpretation [36]. For ex-
ample, the increased seroprevalence of antibodies against ZIKV in the
population makes the inclusion of ZIKV patients in flavivirus test eva-
luations part of accurate test evaluation [36], while acute EBV and CMV
patients are notoriously cross-reactive in a broad range of serological
tests [36–38]. Indeed, the importance of such evaluations was under-
lined by the extremely low specificity we observed for the IgG TBEV
ELISAs. All IgG assays had specificity problems (observed range
12–67%) with regard to the flavivirus panel, while Progen and Reagena
ELISAs had specificity below 80% within the non-flavivirus panel as
well. These observations were in line with the results of a 2013 external
quality assessment (EQA) [33], for which results were submitted for 15
commercially available TBEV IgG ELISAs, including Serion, Progen,
Euroimmun and Siemens. Our observations once again stress the
complexity of interpreting flavivirus serology and the necessity to run
gold standard neutralisation tests, in case infection is presumed on the
basis of IgG responses. This should be emphasised in patients with
presumed exposure to multiple flaviviruses (in the past) or if positive
predictive value is low in the area of exposure.
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In the EU clinical case definition of TBE, “any person with symp-
toms of inflammation of the CNS” should be considered as a clinical
case. [22] Given that the clinical manifestations of TBE can be atypical,
varying from meningitis to meningoencephalomyelitis [39], TBEV is
not always in the differential diagnosis of the treating physician, or
diagnostics are often performed with a delay, particularly in non-en-
demic regions. The official European laboratory definition of TBE [22]
considers TBE to be confirmed when TBEV-specific IgM is detected in
CSF. The presence of IgM in CSF is generally considered as locally
synthesised but ideally, the proper functioning of the BBB should be
assessed in parallel, because the BBB can be impaired by infectious,
inflammatory or metabolic disorders [23].
We aimed to assess the value of a commercially available ELISA in
detecting antibody responses in CSF of eight patients with a clinical
presentation of TBE, in whom paired serum and CSF sampling was done
within several days of the onset of the symptoms. In these patients the
diagnosis TBE could be confirmed, based on the detection of TBE-spe-
cific IgM production in CSF. As IgM was also detected in the serum of all
patients, and taking into account the good performance characteristics
of the used assay, TBEV IgM testing can be regarded as a reliable
diagnostic tool in patients with a neurological disease attributable to
TBEV. Next, we calculated the TBEV IgG AI in seven of the patients with
detectable IgG, and demonstrated that the AI was indicative for local
IgG production in five out of seven cases. It should be emphasised, that
the non-pathological result in two patients does not rule out TBEV as a
cause for the neurological disease, because: 1) IgM was already de-
tected; and 2) the antibody kinetics in CSF are known to be slower than
in serum. [20] Seen in a broader context, calculating an IgG AI will be
of added value, particularly in situations in which IgM might not, or no
longer, be present. IgM responses can for example be altered when
infections occur with a background of another flavivirus infection. Al-
ternatively, TBEV might be part of the diagnostic panel performed late
in the course of the disease, such as in patients with chronic neurolo-
gical disease of unknown aetiology. In these patients, autoimmune
diseases are often part of the work-up, and adequate assessments of
both the functioning of the BBB and the total intrathecal IgG responses
are crucial [23].
Our study has some limitations. As mentioned earlier, there is no
accepted gold standard test for ascertaining the presence of specific
TBEV IgM antibodies. This makes it a challenge to correctly interpret
Fig. 1. Sensitivities and specificities of five ELISAs for the detection of TBEV-specific IgM and IgG antibodies.
C. Reusken, et al. Journal of Clinical Virology 120 (2019) 78–83
81
the performance of the IgM ELISAs, because it cannot be definitively
established that TBEV IgM should be present in certain samples. For this
reason, we have based the IgM interpretation on the agreement of the
assays, which is only a proxy for the correct interpretation of the re-
sults. Furthermore, our study does not include the two other flavi-
viruses that are endemic in parts of Europe, i.e. the Usutu virus and
West Nile virus. Nor did it include samples from TBE patients for which
TBE was a secondary flavivirus infection. This was due to the lack of
availability of these sera to the study consortium at the time of the
study. Finally, background information on the surveyed patients was
limited, whereas it should always be taken into account in clinical de-
cision-making.
In summary, our study shows a crucial role of IgM testing in serum
and CSF to confirm TBEV infection. We demonstrate the importance of
a thorough evaluation of commercially available ELISAs, prior to im-
plementation. Although the compared ELISAs are acceptably sensitive,
the lack of IgG specificity underscores the need for confirmatory testing
by virus neutralisation, particularly if (previous) exposure to multiple
flaviviruses cannot be ruled out. In case of chronic disease, or once IgM
has disappeared, an IgG AI can support the confirmed diagnosis.
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